Topics

Gilead and Glympse partner in clinical development for NASH

08:17 EDT 29 Oct 2019 | Pharmaceutical Technology

Gilead has announced it will be leveraging Glympse Bio’s synthetic biomarker technology to support its nonalcoholic steatohepatitis (NASH) clinical development...
Read More...

The post Gilead and Glympse partner in clinical development for NASH appeared first on Pharmaceutical Technology.

Original Article: Gilead and Glympse partner in clinical development for NASH

NEXT ARTICLE

More From BioPortfolio on "Gilead and Glympse partner in clinical development for NASH"

Quick Search